摘要
参比制剂是仿制药研发的标杆和基础。本文介绍了我国化学仿制药参比制剂的遴选工作背景、遴选原则和路径,美国参比制剂的确定及管理模式,通过分析中美两国参比制剂选择管理的异同,为进一步完善我国参比制剂遴选及管理工作提供参考。
Reference medicinal products are benchmarks and foundations for the research and development of generic drugs.This article introduced the work background,principle,and path of the selection of reference medicinal products of chemical generic drugs in China,the identification and management status of reference listed drugs in America,compared and analyzed the differences in the selection of reference preparations in China and the United States,to provide references for further improving the selection and management of reference medicinal products in China.
作者
游正坤
孙春萌
刘意林
郭志鑫
涂家生
YOU Zheng-kun;SUN Chun-meng;LIU Yi-lin;GUO Zhi-xin;TU Jia-sheng(National Medical Products Administration Key Laboratory for Research and Evaluation of Pharmaceutical Preparations and Excipients,Department of Pharmaceuticals,School of Pharmacy,China Pharmaceutical University,Nanjing 210009,China;Center for Drug Evaluation,National Medical Products Administration,Beijing100022,China)
出处
《中国新药杂志》
CAS
CSCD
北大核心
2022年第24期2458-2464,共7页
Chinese Journal of New Drugs
关键词
参比制剂
选择管理
仿制药
一致性评价
reference medicinal product
selection management
generic drug
consistency evaluation